DSIP
Sleep / neuropeptide
Status & caution. Not FDA-approved. Listed by FDA as 'Emideltide.' Among the 12 peptides removed from Category 2 in April 2026 and scheduled for PCAC review on 24 July 2026. Despite the name, human sleep evidence is inconsistent; effects are not reliably reproduced.
At a glance
Indications & what it's studied for
Marketed for sleep quality, stress resilience, and pain modulation; proposed to influence sleep architecture and stress hormones.
Contraindications & cautions
No established human contraindications; pregnancy data lacking.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Community use reports small evening subcutaneous doses; unvalidated.
Routes of administration
Subcutaneous injection.
Don't combine with
Caution combining with sedatives/CNS depressants.
Reported to stack with
Sometimes paired with GH secretagogues taken at night.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Decades-old neuropeptide literature with mixed results; no robust modern sleep trials.
Before acting on anything here, see Safety & the grey market and how to read a COA.